Pharma MarFRA:PMRA +0.88%83 EBITDA Margin % is 6.31% as of Mar. 2026, which is 16% below its 10-year median of 7.51. GuruFocus rates FRA:PMRA with a GF Score™ of 83/100 and a GF Value™ of €83.37 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Pharma Mar ranks better than 87.62% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pharma Mar's EBITDA for the
three
months ended in Mar. 2026 was €2.7 Mil. Pharma Mar's Revenue for the
three
months ended in Mar. 2026 was €42.9 Mil. Therefore, Pharma Mar's EBITDA margin for the quarter that ended in Mar. 2026 was 6.31%.
Pharma Mar (FRA:PMRA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pharma Mar EBITDA Margin % Related Terms
Pharma Mar EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pharma Mar's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PMRA vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Pharma Mar's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pharma Mar's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Mar (FRA:PMRA) has a EBITDA Margin % of 6.31% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pharma Mar and its competitors. This is 16% below median its historical median of 7.51. According to the industry distribution chart, Pharma Mar ranks #117 out of 945 companies in the Biotechnology industry, placing it in the top 12.4%.
Is Pharma Mar's EBITDA Margin % too high?
Pharma Mar's current EBITDA Margin % of 6.31% is 16% below median its 10-year median of 7.51. Based on the distribution chart, Pharma Mar ranks #117 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma Mar has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #117 out of 945 companies for EBITDA Margin %. This places Pharma Mar in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pharma Mar and its competitors. Pharma Mar's current EBITDA Margin % is 6.31%, which is 16% below median its own 10-year median of 7.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (FRA:PMRA) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.37, compared to a current price of €68.65 — trading 17.7% below its estimated fair value. The current EBITDA Margin % is 6.31%, which is 16% below median its 10-year median of 7.51. Pharma Mar's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pharma Mar (FRA:PMRA), the current EBITDA Margin % is 6.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (FRA:PMRA) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of €68.65 is trading 17.7% below its estimated GF Value™ of €83.37.
GuruFocus considers Pharma Mar to be Modestly Undervalued.
Key valuation signals for FRA:PMRA:
EBITDA Margin %: 6.31% (16% below median its 10-year median of 7.51)
GF Value™: €83.37 vs. price of €68.65 (17.7% below fair value)
No single metric tells the full story. See the FRA:PMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
83GF Score
Get the complete analysis for FRA:PMRA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PMRA has been successfully added to your 
